{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-089887","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.382439+00:00","generated_at":"2026-05-30T11:07:14.904756+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board","bullets":["Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.","He has over four decades of Alzheimer's research and held leadership roles at AstraZeneca and Neurochem.","His expertise will guide InMed's INM-901 drug candidate toward human clinical trials for Alzheimer's disease.","He serves as Editor-in-Chief of 'Alzheimer's & Dementia: Translational Research and Clinical Interventions'."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-089887","json":"https://secwatch.observer/filing/0001213900-24-089887.json","markdown":"https://secwatch.observer/filing/0001213900-24-089887.md","text":"https://secwatch.observer/filing/0001213900-24-089887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/0001213900-24-089887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/ea0218323-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:07:14.904756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}